CINECA IRIS Institutional Research Information System

D'AMBROSIO, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.030
EU - Europa 1.754
AS - Asia 1.270
SA - Sud America 83
OC - Oceania 33
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.203
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.908
IT - Italia 688
CN - Cina 541
DE - Germania 212
SG - Singapore 209
IE - Irlanda 143
JP - Giappone 141
GB - Regno Unito 120
FR - Francia 95
SE - Svezia 85
CA - Canada 79
IN - India 71
ES - Italia 61
VN - Vietnam 54
FI - Finlandia 51
PL - Polonia 51
TR - Turchia 47
ID - Indonesia 46
BR - Brasile 45
NL - Olanda 39
MX - Messico 36
HK - Hong Kong 31
AU - Australia 30
KR - Corea 30
TW - Taiwan 28
AT - Austria 24
UA - Ucraina 23
RU - Federazione Russa 22
CH - Svizzera 19
IL - Israele 18
NO - Norvegia 18
BE - Belgio 16
TH - Thailandia 15
GR - Grecia 14
CO - Colombia 13
AR - Argentina 12
HR - Croazia 11
PT - Portogallo 11
RO - Romania 11
EG - Egitto 9
RS - Serbia 9
MA - Marocco 7
SA - Arabia Saudita 7
DK - Danimarca 6
HU - Ungheria 6
OM - Oman 6
CZ - Repubblica Ceca 5
IR - Iran 5
PE - Perù 5
BY - Bielorussia 4
LT - Lituania 4
MY - Malesia 4
PH - Filippine 4
VE - Venezuela 4
ZA - Sudafrica 4
CR - Costa Rica 3
KE - Kenya 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
PA - Panama 3
PK - Pakistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AM - Armenia 2
CL - Cile 2
EU - Europa 2
LA - Repubblica Popolare Democratica del Laos 2
NG - Nigeria 2
SN - Senegal 2
TN - Tunisia 2
UZ - Uzbekistan 2
BG - Bulgaria 1
EC - Ecuador 1
JO - Giordania 1
LU - Lussemburgo 1
PR - Porto Rico 1
PY - Paraguay 1
QA - Qatar 1
SI - Slovenia 1
Totale 6.203
Salva come PNG Salva come JPEG
Città #
Chandler 273
Fairfield 212
Santa Clara 189
Singapore 161
Ashburn 157
Dublin 141
Redwood City 131
Beijing 128
Houston 119
Woodbridge 109
Wilmington 89
Turin 88
Ann Arbor 86
Seattle 85
Torino 84
Shanghai 76
Cambridge 73
Pisa 54
Nyköping 52
Columbus 51
Milan 51
Jakarta 43
Guangzhou 41
Medford 34
Munich 34
Warsaw 33
Dong Ket 32
Jacksonville 32
Dearborn 31
Rome 31
Princeton 27
Nanjing 26
Villeurbanne 26
Helsinki 25
San Diego 25
Mcallen 24
Hangzhou 22
Montréal 22
Tokyo 21
Chicago 19
Los Angeles 19
Boston 17
Taipei 17
Hong Kong 16
New York 15
Zhengzhou 15
Dresden 14
Wuhan 14
Chengdu 13
Fremont 12
Ottawa 12
Paris 12
Barcelona 11
Bari 11
Madrid 11
Vienna 11
Washington 11
Changsha 10
Indianapolis 10
London 10
Mumbai 10
Amsterdam 9
Ankara 9
Hebei 9
Upper Marlboro 9
Birmingham 8
Bologna 8
Buenos Aires 8
Carrara 8
Freiburg im Breisgau 8
Genoa 8
Heidelberg 8
Istanbul 8
Phoenix 8
San Francisco 8
Seoul 8
Stavanger 8
Sydney 8
Toronto 8
Berlin 7
Cincinnati 7
Fuzhou 7
Hamburg 7
Hefei 7
Palermo 7
Philadelphia 7
Strasbourg 7
Xian 7
Baltimore 6
Billings 6
Bogotá 6
Central 6
Florence 6
Graz 6
Hamilton 6
Irving 6
Leeds 6
Nuremberg 6
Oslo 6
Padova 6
Totale 3.511
Salva come PNG Salva come JPEG
Nome #
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial 1.050
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients 636
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? 509
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 352
Anticoagulation for central venous catheters in patients with cancer. 351
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models 208
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 197
Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 183
Alpha-fetoprotein elevation in NUT midline carcinoma: a case report 182
Preventing Venous Thromboembolism in Patients with Cancer 175
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 157
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy 148
Pazopanib and trametinib as a synergistic strategy against osteosarcoma: Preclinical activity and molecular insights 146
Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature. 133
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways 126
Next generation immune-checkpoints for cancer therapy 120
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 115
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 108
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 107
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. 106
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination 104
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 96
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour 72
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series 68
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 68
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors 67
Parp1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas—a preclinical and translational study 65
Delving into PARP inhibition from bench to bedside and back 56
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma. 55
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 46
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group 44
Eribulin-based treatment in patients affected by sarcomas: a case series 38
How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience 38
What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? 36
First and further-line multidisciplinary treatment of retroperitoneal sarcomas 34
Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions 34
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group 28
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study 28
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas 26
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group 22
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients 22
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets 21
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group 20
A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST) 20
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 19
Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals 17
The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma: The protocol of an international and collaborative effort on an ultra-rare entity 15
Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma 14
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas 13
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis 13
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial 11
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 11
The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials 9
International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease 9
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial 3
Totale 6.351
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.457
article - articoli 0
book - libri 0
conference - conferenze 391
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.848
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020629 0 0 0 0 0 102 82 84 88 97 98 78
2020/2021869 58 57 80 89 76 73 61 68 64 88 55 100
2021/2022725 54 45 52 60 55 44 49 50 42 56 125 93
2022/20231.047 67 66 42 104 88 223 95 96 120 42 65 39
2023/2024755 63 125 60 66 56 76 48 54 8 47 63 89
2024/2025877 53 121 126 115 319 143 0 0 0 0 0 0
Totale 6.351